In the present study, 1 out 5 CP-CML patients treated with nilotinib 400 mg twice daily, compound mutations, including a novel K245N mutation and G250W mutation in BCR-ABL domain were detected. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.